UCB brings promising plaque psoriasis data to EADV 2018

Data derived from two separate sub-analyses suggested that there was "potential value" in switching from Enbrel (etanercept) to Cimzia in inducing and maintaining skin response, both in primary non-responders and those who did respond to initial treatment. Additional findings derived from pooled data of ongoing Phase 3 studies reinforced the durability of efficacy in the drug across indicated doses.

New Phase 2b data also indicated that the use of bimekizumab led to improvements in disease-specific health-related quality-of-life and associated levels of skin clearance.

"This year has proven to be the most ambitious for UCB in immuno-dermatology, and our commitment to this community is clearly seen at this year’s EADV conference," commented said Emmanuel Caeymaex, Head of Immunology and Executive Vice President at UCB. "Growing evidence from all three ongoing Phase 3 Cimzia trials suggests potential value for a range of underserved patient populations living with psoriasis. Following approval earlier this year by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), we are working to reach as many of these patients as possible."

"Also evident at EADV is our commitment to future solutions, including new measures of the value of dual neutralization of both IL-17A and IL-17F provided by our investigational molecule bimekizumab, and research that advances our partnership with physicians working to better address the special needs of women of childbearing age with inflammatory diseases."

Matt Fellows

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.